Anemia Treatment Market

Anemia Treatment Market Analysis

The anemia treatment market size is estimated at USD 12.31 billion in 2025, and is expected to reach USD 17.37 billion by 2030, at a CAGR of 7.12% during the forecast period (2025-2030). Rising global prevalence, faster diagnosis, and successive therapeutic breakthroughs combine to accelerate growth. Intravenous iron and injectable biologics still drive revenue, yet oral HIF-PH inhibitors and gene therapies attract the most attention because they promise easier dosing, better safety, and even curative outcomes. Strengthening nutrition programs in Asia Pacific and Africa widen treatment reach, while AI-enabled point-of-care devices lower diagnostic barriers in resource-constrained settings. Regulatory approvals for products such as CASGEVY underscore how innovation is moving from supportive care to disease modification, supporting sustained investment flows and strategic partnerships.

Global Anemia Treatment Market Trends and Insights

Escalating Worldwide Incidence and Earlier Diagnosis of Anemia

The combined effects of demographic change, improved screening, and AI-supported imaging uncover previously hidden cases across populations. . The World Health Organization reports that 29.9% of women aged 15-49 and 39.8% of children aged 6-59 months suffered from anemia globally, with the African region showing the highest prevalence at 60.2% among children under five.^{[1]Source: World Health Organization, “Global Health Observatory – Anaemia in Women and Children,” who.int} Smartphone-based tests that deliver hemoglobin values in under one minute widen access and help providers intervene sooner, increasing patient volumes in the anemia treatment market.

Growing Prevalence of Comorbid Chronic Diseases

Chronic kidney disease, cancer, and inflammatory disorders each elevate anemia risk and require more complex interventions than iron replacement alone. The 2025 KDIGO guideline recognizes the need to combine ESAs and emerging HIF-PH inhibitors to manage renal anemia safely. As oncology treatment volumes rise, supportive anemia care preserves quality of life for up to 70% of patients receiving chemotherapy, supporting steady demand in the anemia treatment market.

Regulatory Approvals and Pipeline Progress for Novel Therapeutic Classes

Gene editing and oral HIF-PH inhibitors signal a structural shift in treatment standards. FDA clearance of CASGEVY, the first CRISPR-based therapy for sickle cell disease, sets a precedent for curative approaches despite a per-patient cost above USD 3 million. Daprodustat and vadadustat confirmations validate oral modulation of hypoxia-inducible pathways, challenging ESA dominance while reinforcing innovation-led growth for the anemia treatment market.

Government Nutrition Programs for Women of Reproductive Age

Large-scale iron and folic acid supplementation under India’s Anemia Mukt Bharat reaches six priority groups and includes digital testing tools, locking in predictable procurement volumes.^{[2]Source: Ministry of Health and Family Welfare India, “Anemia Mukt Bharat,” nhm.gov.in} Similar initiatives across Southeast Asia and parts of Africa underpin baseline demand for standard iron products, buffering market cycles tied to high-cost biologics.

ESA & Gene-Therapy Cost-Containment Pressures

Payers now require step-therapy, forcing oral iron trials ahead of intravenous options, while biosimilar ESAs chip away at branded pricing. Curative gene therapies face reimbursement hurdles given their high upfront cost, limiting access even where clinical value is clear. Payer policies increasingly emphasize step therapy requirements, mandating oral iron trials before approving expensive intravenous formulations, thereby delaying optimal treatment initiation. The emergence of biosimilar ESAs further pressures originator pricing while HIF-PH inhibitors face uncertainty regarding long-term cardiovascular safety profiles.

Safety Concerns (Thrombo-embolism, Iron Overload) Curb Use

Higher hemoglobin targets with ESAs raise stroke risk and trigger tighter dosing rules. Chronic transfusion accelerates iron overload, and chelation itself can cause liver injury, prompting clinicians to balance efficacy with organ protection. Patient adherence suffers as gastrointestinal side effects from oral iron formulations affect up to 45% of users, with severity correlating with age and BMI, necessitating personalized management strategies that increase healthcare resource utilization.^{[3]Source: Nutrients, “Impact of Side Effects on Anemia Therapy Compliance,” mdpi.com}

Segment Analysis

By Disease Type: Iron Deficiency Drives Volume While Sickle Cell Accelerates Innovation

Iron deficiency anemia accounted for 45.22% of the anemia treatment market size in 2024, underlining its status as the widest clinical segment. High prevalence among women of child-bearing age and children ensures large-scale demand for low-cost iron therapy and supports volume-driven growth across both developed and emerging economies. Government procurement under mass supplementation schemes keeps standard iron products in steady circulation, maintaining leadership despite lower per-unit pricing.

Sickle cell anemia is projected to advance at an 8.61% CAGR, outpacing every other disease subtype within the anemia treatment market. Breakthrough therapies such as CASGEVY and related gene-editing candidates create premium subsegments that attract specialized funding and center-of-excellence models. Growing newborn screening in the United States and selected African countries further enlarges the addressable patient pool and accelerates diagnosis, steering attention toward curative rather than palliative care. The anemia treatment industry therefore sees value migration from high-volume, low-margin iron deficiency products to low-volume, high-margin gene therapies for hemoglobinopathies.

By Therapy Class: Intravenous Iron Leadership Challenged by HIF-PH Innovation

Intravenous iron captured 36.64% of revenue in 2024, supported by hospital protocols that favor rapid hemoglobin correction for severe cases. Products such as ferric carboxymaltose deliver single-dose convenience and reduce admission times, sustaining entrenched usage patterns among clinicians. This class continues to anchor the anemia treatment market, particularly in surgical and obstetric settings where immediate correction prevents transfusion.

HIF-PH inhibitors, forecast to grow at 8.32% through 2030, aim to close efficacy gaps in chronic kidney disease by stimulating endogenous erythropoietin under physiological limits. Oral delivery removes injection burdens, giving patients more autonomy and simplifying logistics in dialysis centers. Continued positive cardiovascular safety data could push these agents toward first-line status, gradually trimming dependence on ESAs. The anemia treatment industry thus balances a reliable intravenous iron base with an innovation pipeline that redefines long-term management.

By Route of Administration: Injectable Dominance Faces Oral Innovation Challenge

Injectables held 61.75% of 2024 revenue owing to entrenched use of ESAs, IV iron, and gene-based infusions. Hospital routines, cold-chain reliability in developed markets, and clinician familiarity secure ongoing preference for parenteral delivery. These factors safeguard current volume in the anemia treatment market even as payer pressure mounts.

Oral routes, advancing at 7.83% CAGR, receive momentum from tolerability-focused reformulations such as ACCRUFeR, which mitigates gastrointestinal distress for more than 50% of traditional ferrous-salt users. HIF-PH inhibitors exclusively rely on oral dosing, making convenience a key competitive lever. As consumer preference shifts toward home-based care, oral products are positioned to win incremental share, giving the anemia treatment market a dual-track structure of hospital-centric injectables and community-based oral regimens.

Geography Analysis

North America generated 37.43% of total sales in 2024, reflecting early adoption of premium therapies and insurance frameworks that reimburse high-cost gene editing, ESA biologics, and injectable irons. Comprehensive newborn screening and precision-medicine programs bolster uptake across rare anemia segments. Payer scrutiny, however, caps ESA growth and encourages biosimilar use, shaping a value-oriented procurement environment that still rewards innovation when strong clinical outcomes are demonstrated.

Europe presents steady but more price-sensitive expansion. Harmonized regulatory reviews permit rapid biosimilar penetration, spreading access to established biologics while containing costs. Countries such as Germany and the United Kingdom have adopted pathway funding for CRISPR therapies, yet negotiate outcomes-based contracts to align high upfront payments with long-term clinical benefit. Iron chelation combinations receive acceptance after favorable safety and efficacy evidence, reinforcing diversified therapy mixes across national health services.

Asia Pacific is the fastest-growing region at 8.45% CAGR through 2030, driven by widening insurance coverage, rising chronic disease loads, and government-led nutrition drives. China’s regulatory reforms speed approval of HIF-PH inhibitors, while domestic manufacturers scale generic IV iron, lowering average selling prices and boosting penetration. Smartphone-enabled diagnostics further lift test volumes, feeding prescription demand throughout the anemia treatment market.

Competitive Landscape

The anemia treatment market hosts a blend of diversified pharma leaders and niche biotechs, producing moderate concentration. GSK, Pfizer, Novartis, Takeda, and Amgen defend legacy franchises in ESAs and iron solutions by leveraging distribution reach and post-marketing safety data. Vertex Pharmaceuticals and CRISPR Therapeutics elevate competitive stakes with the first curative gene-editing therapy, forcing incumbents to reassess R&D strategies.

Strategic partnering accelerates pipeline depth: Takeda’s USD 1.3 billion licensing deal for rusfertide underscores appetite for mechanisms that address iron regulation disorders. Sanofi’s USD 9.5 billion acquisition of a blood-disorder specialist signals scale-up intent among big pharma to command high-value rare-disease niches. AI-driven discovery firms collaborate with established manufacturers to identify novel PHD inhibitors, cutting development time and differentiating future offerings.

Digital health integration becomes a competitive necessity. Drug makers increasingly provide connected devices that monitor hemoglobin or dosing adherence, building service ecosystems around products. Companies exploring combination therapies—for example, pairing oral iron with absorption enhancers—aim to simplify regimens and improve outcomes. Overall, competitors that combine clinical innovation, digital enablement, and localized pricing strategies capture growing influence within the anemia treatment industry.